The U.S. government has released its 2026 Medicare Advantage and prescription drug plan quality ratings, offering insight into how major health insurers performed in providing care to seniors. These annual ratings, issued by the Centers for Medicare & Medicaid Services (CMS), play a key role in determining bonus payments to insurers—worth hundreds of millions or even billions of dollars—and influence plan revenues in 2027.
According to CMS data, CVS Health’s Aetna stands out with over 81% of members enrolled in top-rated plans, while UnitedHealth Group follows closely with 78%. Elevance Health improved significantly, reaching 55% of members in 4-star or higher plans, compared to 40% last year. In contrast, Humana saw only about 20%, or 1.2 million members, in highly rated plans.
Overall, 64% of all Medicare Advantage members with prescription drug coverage are enrolled in plans rated four stars or higher, according to Oppenheimer analysts. These ratings assess factors such as customer satisfaction, access to care, chronic disease management, and preventive health screenings, ensuring seniors can make informed choices when selecting coverage.
CVS Health said more than 63% of its Aetna Medicare Advantage members are in 4.5-star plans for next year. Meanwhile, UnitedHealth reported that 40% of its members are enrolled in 4.5-star or higher plans, consistent with its earlier projections. Analysts described this year’s results as largely expected, following recent company updates.
Centene’s Wellcare, led by CEO Michael Carson, also reported continued improvement, emphasizing the company’s focus on delivering high-quality, affordable healthcare and enhancing health outcomes nationwide.
As competition intensifies, star ratings continue to shape the landscape of the Medicare Advantage market, rewarding insurers that excel in quality and member satisfaction while motivating others to raise their standards.


Pfizer Secures $10 Billion Deal for Obesity Drug Developer Metsera, Outbids Novo Nordisk
Pfizer Sues Novo Nordisk Over Alleged Tactics to Block Obesity Drug Competition
iRobot Files for Chapter 11 Bankruptcy Amid Rising Competition and Tariff Pressures
Rio Tinto Signs Interim Agreement With Yinhawangka Aboriginal Group Over Pilbara Mining Operations
Apple App Store Injunction Largely Upheld as Appeals Court Rules on Epic Games Case
Moore Threads Stock Slides After Risk Warning Despite 600% Surge Since IPO
Nvidia Weighs Expanding H200 AI Chip Production as China Demand Surges
California Jury Awards $40 Million in Johnson & Johnson Talc Cancer Lawsuit
FDA Names Tracy Beth Høeg as Acting CDER Director After Richard Pazdur Announces Retirement
Eli Lilly’s Inluriyo Gains FDA Approval for Advanced Breast Cancer Treatment
Azul Airlines Wins Court Approval for $2 Billion Debt Restructuring and New Capital Raise
China to Add Eli Lilly’s Mounjaro to National Health Insurance in 2025
Woolworths Faces Fresh Class Action Over Alleged Underpayments, Shares Slide
SK Hynix Considers U.S. ADR Listing to Boost Shareholder Value Amid Rising AI Chip Demand
United Airlines Tokyo-Bound Flight Returns to Dulles After Engine Failure
Nomura Expands Alternative Assets Strategy With Focus on Private Debt Acquisitions
HSBC’s $13.6 Billion Take-Private Offer for Hang Seng Bank Gains Board Backing 



